KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Shares Outstanding (Diluted Average) (2020 - 2026)

Aquestive Therapeutics has reported Shares Outstanding (Diluted Average) over the past 6 years, most recently at $106.9 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 23.29% year-over-year to $106.9 million; the TTM value through Dec 2025 reached $106.9 million, up 23.29%, while the annual FY2025 figure was $106.9 million, 23.29% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $106.9 million at Aquestive Therapeutics, down from $110.6 million in the prior quarter.
  • Over five years, Shares Outstanding (Diluted Average) peaked at $110.6 million in Q3 2025 and troughed at $35.6 million in Q1 2021.
  • A 5-year average of $67.0 million and a median of $63.0 million in 2023 define the central range for Shares Outstanding (Diluted Average).
  • Biggest five-year swings in Shares Outstanding (Diluted Average): skyrocketed 77.96% in 2023 and later decreased 0.24% in 2024.
  • Year by year, Shares Outstanding (Diluted Average) stood at $38.1 million in 2021, then grew by 27.99% to $48.7 million in 2022, then grew by 25.69% to $61.3 million in 2023, then surged by 41.58% to $86.7 million in 2024, then increased by 23.29% to $106.9 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for AQST at $106.9 million in Q4 2025, $110.6 million in Q3 2025, and $97.4 million in Q2 2025.